Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2020

Zhao Shen, Fang Wenfeng, Pan Hui, Yang Yunpeng, Liang Ying, Yang Lin, Dong Xiaorong, Zhan Jianhua, Wang Kai, Zhang Li

Abstract excerpt

INTRODUCTION: HER2 exon 20 insertion (ex20ins) is one of the most intractable problems in lung cancer. Most ex20ins are resistant to available EGFR or pan-HER tyrosine kinase inhibitors (TKIs), with the exception of a few mutants. However, the mechanism for TKI response and resistance of HER2 ex20ins remains poorly understood. METHODS: Next-generation sequencing-based genomic profiling data of 4139 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Molecular Docking Simulation

Share to Protein Kinase Inhibitors

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 32036069
DOI: 10.1016/j.jtho.2020.01.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.PMID 32036069Read ↗

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase InhibitorsSemantic proximity Read ↗

STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20–Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer ModelsSemantic proximity Read ↗

Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL)Semantic proximity Read ↗

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.Semantic proximity Read ↗

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments.Semantic proximity Read ↗

The prediction of treatment outcome in NSCLC patients harboring an EGFR exon 20 mutation using molecular modeling.Semantic proximity Read ↗

EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read ↗

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.Semantic proximity Read ↗

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.Semantic proximity Read ↗

Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets.Semantic proximity Read ↗

The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives.Semantic proximity Read ↗

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.